# A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

> **NCT03515785** · — · WITHDRAWN · sponsor: **Incyte Biosciences International Sàrl**

## Conditions studied

- BCR-ABL Positive Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03515785
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-31
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Revisiting the availability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward.
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515785, "A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03515785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*